142 related articles for article (PubMed ID: 29237803)
1. Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in
Smith KM; Fagan PC; Pomari E; Germano G; Frasson C; Walsh C; Silverman I; Bonvini P; Li G
Mol Cancer Ther; 2018 Feb; 17(2):455-463. PubMed ID: 29237803
[TBL] [Abstract][Full Text] [Related]
2. Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein.
Fischer H; Ullah M; de la Cruz CC; Hunsaker T; Senn C; Wirz T; Wagner B; Draganov D; Vazvaei F; Donzelli M; Paehler A; Merchant M; Yu L
Neuro Oncol; 2020 Jun; 22(6):819-829. PubMed ID: 32383735
[TBL] [Abstract][Full Text] [Related]
3. Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report.
Kubota Y; Kawano M; Iwasaki T; Itonaga I; Tsumura H; Kaku N; Tanaka K
Medicine (Baltimore); 2023 Dec; 102(49):e36232. PubMed ID: 38065851
[TBL] [Abstract][Full Text] [Related]
4. A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib.
Hashiguchi MH; Sato T; Watanabe R; Kagyo J; Matsuzaki T; Domoto H; Kato T; Nakahara Y; Yokose T; Hiroshima Y; Shiomi T
Thorac Cancer; 2021 Sep; 12(18):2504-2507. PubMed ID: 34319660
[TBL] [Abstract][Full Text] [Related]
5. Post-HSCT Maintenance Treatment Using Entrectinib for an AML Patient Accompanied with ETV6::NTRK3: A Case Report.
Zhao X; Hao M; Zhang X; Wei J; Feng S; He Y; Jiang E; Han M
Onco Targets Ther; 2023; 16():1055-1059. PubMed ID: 38144903
[TBL] [Abstract][Full Text] [Related]
6. ETV6-NTRK2 Fusion in a Patient With Metastatic Pulmonary Atypical Carcinoid Successfully Treated With Entrectinib: A Case Report and Review of the Literature.
Zhang W; Tian S; Li X; Chen Y; Wang X; Zhang Y; Lv L; Li Y; Shi H; Bai C
Clin Lung Cancer; 2024 May; 25(3):215-224.e3. PubMed ID: 38584068
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours.
Paz-Ares L; Barlesi F; Siena S; Ahn MJ; Drilon A; Conley A; Rolfo C; Wolf J; Seto T; Doebele R; Kapre A; Chen D; McCallum S; Osborne S; Demetri G
ESMO Open; 2021 Jun; 6(3):100113. PubMed ID: 33930659
[TBL] [Abstract][Full Text] [Related]
8. The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer.
Roth JA; Carlson JJ; Xia F; Williamson T; Sullivan SD
J Manag Care Spec Pharm; 2020 Aug; 26(8):981-986. PubMed ID: 32329651
[TBL] [Abstract][Full Text] [Related]
9. Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Fan Y; Drilon A; Chiu CH; Loong HHF; Siena S; Krzakowski M; Dziadziuszko R; Zeuner H; Xue C; Krebs MG
Clin Lung Cancer; 2024 Mar; 25(2):e81-e86.e4. PubMed ID: 38245456
[No Abstract] [Full Text] [Related]
10. Development of a Cell Line Containing the Chimeric ETV6-NTRK3 Gene. The Search for Mutations of the Tyrosine Kinase Chimeric Domain That Cause Resistance to Larotrectinib.
Boyarskikh UA; Savostyanova TA; Oscorbin IP; Filipenko ML
Bull Exp Biol Med; 2023 May; 175(1):132-137. PubMed ID: 37338765
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: A mini review.
El-Nassan HB; Al-Qadhi MA
Eur J Med Chem; 2023 Oct; 258():115618. PubMed ID: 37413881
[TBL] [Abstract][Full Text] [Related]
12. Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With
Hanf D; Heining C; Laaber K; Nebelung H; Uhrig S; Hutter B; Jahn A; Richter D; Aust D; Herbst F; Fröhling S; Glimm H; Folprecht G
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250401
[No Abstract] [Full Text] [Related]
13. Discovery of novel 3-(1H-pyrazol-4-yl)-1H-indazole derivatives as potent type II TRK inhibitors against acquired resistance.
Qin Q; Guo Z; Lu S; Wang X; Fu Q; Wu T; Sun Y; Liu N; Zhang H; Zhao D; Cheng M
Eur J Med Chem; 2024 Jan; 264():115953. PubMed ID: 38029466
[TBL] [Abstract][Full Text] [Related]
14. Prediction of ROS1 and TRKA/B/C occupancy in plasma and cerebrospinal fluid for entrectinib alone and in DDIs using physiologically based pharmacokinetic (PBPK) modeling approach.
Chen L; Yao N; Yang H; Zhang S; Zhang K
Cancer Chemother Pharmacol; 2024 Feb; 93(2):107-119. PubMed ID: 37838624
[TBL] [Abstract][Full Text] [Related]
15. ALK Inhibitor Response in Melanomas Expressing
Couts KL; Bemis J; Turner JA; Bagby SM; Murphy D; Christiansen J; Hintzsche JD; Le A; Pitts TM; Wells K; Applegate A; Amato C; Multani P; Chow-Maneval E; Tentler JJ; Shellman YG; Rioth MJ; Tan AC; Gonzalez R; Medina T; Doebele RC; Robinson WA
Mol Cancer Ther; 2018 Jan; 17(1):222-231. PubMed ID: 29054983
[TBL] [Abstract][Full Text] [Related]
16. A novel EML4-NTRK3 fusion in lung adenocarcinoma with dramatic response to entrectinib.
Batra U; Nathany S; Sharma M; Jain P; Mehta A; Bansal A
J Cancer Res Ther; 2023 Oct; 19(7):2045-2047. PubMed ID: 38376315
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and evaluate of indazolylaminoquinazoline derivatives as potent Tropomyosin receptor kinase (TRK) inhibitors.
Xu Y; Zhao W; Zhang X; Yu X; Chen Y; Wang Z; Chu Y; Zhu X; Zhang P
Bioorg Med Chem; 2024 Feb; 99():117608. PubMed ID: 38271867
[TBL] [Abstract][Full Text] [Related]
18. Discovery, Optimization, and Evaluation of Novel Pyridin-2(1
Xu Z; Peng X; Zhang R; Ji Y; You M; Wang D; Shen Y; Zheng M; Li C; Ai J; Liu H
J Med Chem; 2024 Jan; 67(2):1168-1183. PubMed ID: 38227770
[TBL] [Abstract][Full Text] [Related]
19. Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations.
Wang Z; Wang J; Wang Y; Xiang S; Zhou H; Song S; Song X; Tu Z; Zhou Y; Ding K; Zhang ZM; Zhang Z; Lu X
J Med Chem; 2023 Sep; 66(18):12950-12965. PubMed ID: 37676745
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated
Mayr L; Guntner AS; Madlener S; Schmook MT; Peyrl A; Azizi AA; Dieckmann K; Reisinger D; Stepien NM; Schramm K; Laemmerer A; Jones DTW; Ecker J; Sahm F; Milde T; Pajtler KW; Blattner-Johnson M; Strbac M; Dorfer C; Czech T; Kirchhofer D; Gabler L; Berger W; Haberler C; Müllauer L; Buchberger W; Slavc I; Lötsch-Gojo D; Gojo J
J Pers Med; 2020 Dec; 10(4):. PubMed ID: 33353026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
